chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Nerve pain status post COVID-19 vaccination -with a shot which appears to have been given in a location that was in the superior portion of the deltoid.  This resulted in some immediate discomfort but is progressed to nerve pain involving the shoulder and neck without evident skin reaction involved We will empirically prescribe prednisone course and gabapentin detailed PAR-Q done
FEVER; This spontaneous report received from a consumer concerned a female of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow up will be requested for this case. No concomitant medications were reported. On an unspecified date, the subject experienced fever. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of fever was not reported. This report was non-serious. This case, from the same reporter is linked to 20210744057 and 20210744087.
Since 15 December he has complained of recurrent episodes of localized itching and rashes described as raised, red, itchy welts which can occur anywhere on his body and typically occur at sites of pressure or where his skin is scraped or scratched. Lesions last less than 24 hours, spare his palms and soles, and resolve without post-inflammatory changes. Single episode of facial swelling which led him to present to the ER on 17 December where he was treated with oral H1 and H2 antihistamines and Prednisone with transient improvement. He denies generalized cutaneous, laryngeal, pulmonary, GI/GU, neurologic, and cardiovascular symptoms with these episodes. Episodes not associated with heat, exercise, sweating, cold, foods, medications, NSAIDs, IV contrast, latex exposure, infections, or insect bites/stings. He received his Moderna COVID-19 vaccine booster dose on 6, nine days prior to onset of symptoms. He has used oral antihistamines with control of symptoms. He denies constitutional symptoms. UCT score today is 18 (1, 2, 3, 4, 1, 4, 2, 1).
The patient presented to the pharmacy with a red blistering bumpy rash trailing down the outside of her left lateral leg. It appears to be a varicella-like/zoster-like rash.
Localized erythema and induration  R deltoid. Dizziness, fever, HA within 24 hours of admin. Treated wth Benadryl, Motrin and rest.
TOOK TWO DOSES IN A ROW; This spontaneous case (PVX2019-2349) was received from a healthcare professional on 12-Sep-2019. It described a male consumer who "took two doses in a row" (PT: Inappropriate schedule of vaccine administered), while being on Vivotif for an unknown indication.  Case report: The consumer did not take Vivotif according to the schedule. He took the second and the third dose on consecutive days and did not have any problem.  Action taken with Vivotif with respect to the event was not applicable.   The clinical outcome of the reported event was unknown.  Company's Comment: The causality of the event "took two doses in a row" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event "took two doses in a row" was considered as not applicable.
Administration of Expired Vaccine; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administration of Expired Vaccine) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administration of Expired Vaccine). On 15-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Administration of Expired Vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications was reported.  Treatment Information was not provided by Reporter.   This case was linked to MOD-2021-115609, MOD-2021-115643, MOD-2021-115655, MOD-2021-115657, MOD-2021-115659, MOD-2021-115661, MOD-2021-115662, MOD-2021-115665, MOD-2021-115666, MOD-2021-115667, MOD-2021-115691, MOD-2021-115695, MOD-2021-115701 (Patient Link).
This case was reported by a consumer via call center representative and described the occurrence of pain in arm n a 76-year-old female patient who received SHINGRIX. Concurrent medical conditions included arthritis. Concomitant products included Vitamin D3. On 3rd May 2018, the patient received the 1st dose of SHINGRIX (intramuscular). On 3rd May 2018, less than a day after receiving SHINGRIX, the patient experienced pain in arm. The patient was treated with Ice Pack (NOS). On an unknown date, the outcome of the pain in arm was not recovered/not resolved. The reporter considered the pain in arm to be related to SHINGRIX. Additional information was reported as follows: The patient's concomitant product included heart pill, vitamin and blood thinner. On 3rd May 2018 18:00 hours, the patient received SHINGRIX in left arm. The patient experienced pain in her left arm. On the reporting day, the patient's pain was so bad that she could not get out of the bed on her own. The patient had been applying ice to her arm. The patient had denied permission to contact their physician.
2nd dose: no ae events   1 nd dose:12/24/20 07:30 PM Heavy head at awakening 4:30 AM, spouse drove pt to work; brain fogginess, fatigue arriving home; pt did not eat for 2 days, lethargic; forced self to hydrate; missed work for 4 days. Large lesion roof of mouth l side to larger two front teeth, very painful, Veltrax PCP.  Pt regained appetite as lesion went down in mouth. Lesion has resolved, all other symptoms have resolved.
Redness at the vaccine site; Redness at the vaccine site/itchy; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION SITE ERYTHEMA (Redness at the vaccine site) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history.). Concomitant products included ATORVASTATIN CALCIUM (LIPITOR), AMLODIPINE BESILATE (NORVASC), VALSARTAN, FISH OIL, ASCORBIC ACID (VITAMIN C PLUS [ASCORBIC ACID]), VITAMIN D3 and UBIDECARENONE (COQ10 [UBIDECARENONE]) for an unknown indication.    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE ERYTHEMA (Redness at the vaccine site). At the time of the report, VACCINATION SITE ERYTHEMA (Redness at the vaccine site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment information was not provided.
Nov 10 - Approx 6 hours after shot administered, I began having chest pain.  I went to the hospital that night and they kept me overnight.  The next morning, I failed a nuclear stress test and underwent a catheterization which showed no blockages Dec 15 - I went to an Urgent Car facility suspecting I had Covid due to shortness of breath and not feeling well.  Negative Covid Tests )both rapid and PCR) Dec 17 - I went to the hospital for shortness of breath and a CT Scan with contrast showed several small Pulmonary Emboli
pt devel a gen arthritic type rxn & joint pain in wrists & ankles;
Got sleepy; This spontaneous case was reported by a consumer and describes the occurrence of   in an 84-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided. The reporter stated that her husband got sleepy after his Moderna vaccine. Treatment for the event was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: received and updated the Event duration and outcome
Patient is 16 years of age.  The vaccine is only authorized for patients 18 y/o and above.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE INSOMNIA W SLEEP APNEA
Injection given 9/26/09 at about 5:30 pm. Patient called 9-27-09 at about 11 AM saying she had intense itching on legs and was moving up the body. Told her to take 2 BENADRYL and go to ER if it worsens.
Mother of child calls clinic 06/11/02 at 8:50AM to state child cried throughout the night and spit up once at 5AM. Advised to alternate Tylenol with Advil-dosage for age. Applied warm moist packs to area encourage fluids and continue to monitor. 06/12/02 8:20AM baby-sitter states pt slept through the night no crying." 06/12/02 14:40pm, mother noted blotchy area on left thigh examined by doctor. No fever and child active welt noted on left thigh.
rash; scratching and itching so bad; bruising; This is a spontaneous report from a contactable consumer (patient). A 78-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number and expiration date not reported), via an unspecified route of administration on 11Feb2021 at 13:45 (at the age of 78-years-old) at dose 1, single in the left arm for COVID-19 immunisation. Medical history included heart problems and triple bypass, both about 9 years ago. The patient's concomitant medications were not reported. On 12Feb2021, the patient experienced a rash after receiving the first dose of the Pfizer COVID-19 vaccine. The patient was asking if she should still get the second dose. The patient saw her doctor today for the rash. The patient's doctor saw that the rashes breakout on all of the patient's body. The patient took Benadryl tablet as treatment for the rash. On Sunday, on an unspecified date in 2021, the patient was scratching and itching so bad and was bruising herself. Since the dosage on the label was two tablets for an adult, the patient has taken two tablets each day since then. The patient stated that her rash seems to have new ones and today. In the morning, there seemed to be new ones, mostly on her back and on her front. There were not too many on her arms and legs, but mostly, the rash was on the patient's body. The patient cannot see her back, but her doctor looked at her back and said that there was a lot. The patient said that she was usually not allergic to anything, and has taken a lot of different medications, even trial drugs, and those didn't bother her. The patient received treatment of Benadryl for all the events. Outcome of all the events was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Since having the vaccine first dose, I have started having coughing in the evening when I lay down. It is intense enough that I have to do a nebulizer breathing treatment of Albuterol about twice a night to get through the night and be able to sleep. This is something that is still happening almost three months after my first dose.  I have never had this condition before.
Fatigue/some fatigue after receiving your first SHINGRIX vaccine; This case was reported by a consumer via call center representative and described the occurrence of fatigue in a 70-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced fatigue. On an unknown date, the outcome of the fatigue was unknown.   It was unknown if the reporter considered the fatigue to be related to Shingrix.     Additional Information: GSK receipt date: 02-Nov-2022 Reporter's comment:  The case was reported by patient. The patient received the first dose of Shingrix vaccine. The patient asked how long fatigue would last as side effect of the vaccine. The patient experienced some fatigue after receiving the first dose of Shingrix vaccine.
Gave combination vaccines indicated for 4-6 years of age to 7 year old patient.  No injury or adverse effect noted.
The polyneuropathy increased 10-fold after the Pfizer vaccine for the first 2 days after the first shot and even worse after the 2nd shot.; fever; This is a spontaneous report from a contactable consumer (patient). This is the second of two reports.     A 65-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 intramuscular, administered in Arm Left on 16Jul2021 14:00 (Lot Number: EW0198) as single dose (at 65 years old)  for COVID-19 immunisation.  The vaccine was administered at Pharmacy or Drug store. Medical history included Guillain-barre syndrome from Oct1986 to Apr1987 (Paralyzed waist down), breast cancer from Aug2015 to Jul2016 (Right mastectomy reconstruction), lung neoplasm malignant from Jan2020 to Jan2020. Concomitant medications were not reported. Previously the patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) Lot number: EW0173 on 25Jun2021 (at 64 years old) for COVID-19 immunisation and experienced polyneuropathy. The patient previously also received tetanus boost on 04Jun2017 for immunization and experienced polyneuropathy and muscle weakness.  The patient experienced the polyneuropathy increased 10-fold after the Pfizer vaccine for the first 2 days after the first shot and even worse after the 2nd shot in Jul2021 with outcome of recovering, fever in Jul2021 with outcome of unknown. No treatment required for polyneuropathy. The patient underwent lab tests and procedures which included central nervous system infection: negative in 2017, central nervous system infection: negative  in 2019, central nervous system infection: negative in 2020, chest x-ray: positive in Jan2020, lumbar puncture: negative in Oct1986, mammogram: positive in Aug2015, x-ray: negative in Oct1986.  Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202100908602 same patient, different event and dose
Information has been received from a consumer concerning his 17 year old daughter with no pertinent medical and no known drug allergies/drug reactions who on 20-APR-2009 was vaccinated with the third dose of GARDASIL. There was no concomitant medication. It was reported that the patient has been experiencing hair loss after receiving GARDASIL. The caller stated that his "daughter's hair was turning thin and brittle and it was falling out in clumps while taking a shower". It was also reported that "she has less than a quarter of the amount of hair that she used to have from a year ago". There were no laboratory diagnostic tests performed. The patient sought medical attention with an office visit. Additional information has been requested.
On 03/10/2021 Pt presented to clinic for follow up of recent hospitalization.  During visit Provider noted a rash above his left eye.  Pt reports that he noticed it a "few" hours after his 2nd Covid-19 vaccine, which was given on 03/08/2021.  Pt describes it as "achy".   Pt denies pruritus.  No adverse reaction reported on 1st vaccine done on 01/25/2021. Rash not present anywhere besides above left eye.  No evidence or report of systemic symptoms. Provider dx as shingles.  Pt prescribed valACYclovir 1g 1 tab q 8 hours x 7 days.  Pt referred to ophthalmologist as precaution.  Pt was not seen until today, no report yet.
Pt received adult dose hepatitis A vaccine instead of pediatric dose. No adverse reaction noted or reported. Pt's mother is aware.
Swelling of entire left arm. Pressure and pain, red, and warm. Treatment by ice and Benadryl 25 mg q 6 h.
9:00 am - vaccine  10:00 am - 5:00 pm - sore arm  5:00 pm - 8:30 pm - body aches chills fever  8:30 pm - passed out  8:45 pm - passed out again (ambulance came and took me to the ER)  9:00 pm - passed out for the third time in the ambulance  9:00 pm - 1:00 am - in the ER. tests were given. everything came back normal. discharged.
"COVID arm" Delayed allergic reaction - redness, rash, swelling and pain around injection site in a patch about the size of a compact disc. I had my period the day of the second injection and got it again right on time four weeks later, but it has been an unusually heavy flow with almost constant large blood clots. This is abnormal for me.
my results came back stating I was positive; feel ill with a severe back pain on my left side. The same side where I was given the shot; cough; runny nose; headaches; a lot of pain in my bones; a lot of pain in my bones, and eye lids; Feel ill; This is a spontaneous report from a consumer (patient). A 65-year-old female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date unknown), via an unspecified route of administration on the left arm on 25Jan2021 at 11:00 at the age of 65 years old at a single dose for COVID-19 immunisation at the school/student Health Clinic. Medical history was none. The patient has no allergies to medications, food and other products. The patient is not pregnant and was not pregnant at the time of vaccination. There were no concomitant medications. The patient was not diagnosed with COVID-19 prior to vaccination. On 26Jan2021 at 07:00, patient began to feel ill with a severe back pain on her left side. The same side where she was given the shot. In addition, patient also experienced a cough, runny nose, headaches, a lot of pain in my bones, and eye lids. At first, she believed it was due to the vaccine but as she got worse, she decided to take a COVID test (nasal swab) on 31Jan2021 and the results came back stating she was positive. Since then the patient has been in quarantine. No treatment was received in response to the events. The patient was recovering from the events. The patient has a second vaccination appointment scheduled on 13Feb2021 and would like to know if she will still go as scheduled or will she need to go in a later date.    Information on the lot/batch number has been requested.
Immediately felt arms and legs go cold and tingling. Had trouble breathing with rapid heart rate. Subsidied after 20 mins but popped back up through the night in smaller instances. Day 2: sore arm, body aches muscle pains tingles- felt like vision was in HDR   Day 3: fever 100 F, severe headache, body aches and tired overall felt weird Day:4 still feel weird/off, vision changes - have trouble seeing distance and focusing when prior had perfect 2020 vision
w/in 15-30 seconds of recv vax;pt c/o lightheadedness, arched back & had tremors for 30 seconds, confused upon regaining consciousness, taken to hosp;
I developed fever (highest 101.6), chills, body aches, and headache that lasted approximately 15 hours. Fever/body aches was able to be control with Tylenol and Advil. I have never had this strong of an immune response to a vaccine before.
Information has been received from a pharmacist concerning a female who, at an unknown date in her childhood, was vaccinated with a dose of mumps virus vaccine live (Jeryl Lynn). It was reported that the patient had mumps twice since vaccination with mumps virus vaccine live. The patient was being given pain medication for her discomfort. The patients status was reported as not recovered. Unspecified medical attention was sought. No product quality complaint was involved. Additional information has been requested.
Starting day 2 and continued to day 3  very sore arm with large red swelled area, vertigo, diarrhea, nausea, loss of appetite
This spontaneous report as received from a registered nurse refers to a 11-year-old female patient - her daughter. The patient's concurrent conditions included asthma. The patient did not have any allergies. There were no concomitant medications and medical history reported. On 10-AUG-2015, the patient was vaccinated with first dose of GARDASIL (route of administration, dose, lot number and expiration date were not reported). On 10-AUG-2015, after vaccination, the patient experienced a headache and was "not feeling right". On 15-AUG-2015, the patient started to experience "severe abdominal cramping" that lasted between 2-3 hours. Since the abdominal cramping started, the patient experienced sporadic, bright red, vaginal bleeding. The vaginal bleeding was described as "gushing" and/or "spotting" at different times. The patient did not receive any treatment. There was no lab diagnostics studies performed. The outcome of the events was unknown. The relatedness between the event and GARDASIL was not reported. Additional information has been requested.
Tingling sensation in the face, tightness in the throat, and redness on the arms and chest  Benadryl 25 mg po once given
To date, symptoms have persisted for five days. They include: fatigue, joint pain, neck stiffness, headache, left arm pain; continued redness, pain and topical heat at site of injection.
Rash on neck, face, forearm; Rash on neck, face, forearm; Rash on neck, face, forearm; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 12Mar2021 at 09:15 (at the age of 25-year-old), as a single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient did not have any allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within 2 weeks of vaccination. On 16Mar2021, the patient experienced rash on neck, face and forearm. The patient did not receive any treatment for the reported event. The clinical outcome of rash on neck, face, forearm was not resolved at the time of reporting.   Amendment: This follow-up report is being submitted to amend previously reported information: 1. recoded event term for "Rash on neck, face, forearm" 2. Updated final sentence as No follow-up attempts are possible; information about lot/batch number cannot be obtained  No follow-up attempts are possible; information about lot/batch number cannot be obtained.